MX2016000293A - Biomarcadores del trastrono del espectro autista. - Google Patents
Biomarcadores del trastrono del espectro autista.Info
- Publication number
- MX2016000293A MX2016000293A MX2016000293A MX2016000293A MX2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A
- Authority
- MX
- Mexico
- Prior art keywords
- autism
- metabolites
- spectrum disorder
- metabolic signatures
- autism spectrum
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 3
- 239000000090 biomarker Substances 0.000 title 1
- 230000002503 metabolic effect Effects 0.000 abstract 3
- 239000002207 metabolite Substances 0.000 abstract 3
- 206010003805 Autism Diseases 0.000 abstract 2
- 208000020706 Autistic disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000004949 mass spectrometry Methods 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/70—Machine learning, data mining or chemometrics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844128P | 2013-07-09 | 2013-07-09 | |
| US201461996835P | 2014-05-14 | 2014-05-14 | |
| PCT/US2014/045397 WO2015006160A2 (en) | 2013-07-09 | 2014-07-03 | Biomarkers of autism spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016000293A true MX2016000293A (es) | 2016-06-21 |
Family
ID=52280698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000293A MX2016000293A (es) | 2013-07-09 | 2014-07-03 | Biomarcadores del trastrono del espectro autista. |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10060932B2 (enExample) |
| EP (1) | EP3019624B1 (enExample) |
| JP (1) | JP6763770B2 (enExample) |
| CA (1) | CA2917483A1 (enExample) |
| MX (1) | MX2016000293A (enExample) |
| WO (1) | WO2015006160A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| WO2017197252A1 (en) * | 2016-05-13 | 2017-11-16 | Stemina Biomarker Discovery, Inc. | Autism subsets |
| KR102328323B1 (ko) | 2017-03-31 | 2021-11-19 | 엑시얼 테라퓨틱스, 인크. | 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제 |
| US12080432B1 (en) | 2017-06-01 | 2024-09-03 | The Regents Of The University Of Colorado | Plasma metabolome as a predictor of biological aging |
| EP3746796A4 (en) * | 2018-01-29 | 2021-12-22 | Stemina Biomarker Discovery, Inc. | DIAGNOSIS AND TREATMENT OF AUTISTIC SPECTRUM DISORDERS BASED ON METABOTYPES CONTAINING AN AMINE |
| CN109813912B (zh) * | 2019-01-04 | 2021-12-28 | 深圳大学 | 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用 |
| CA3136303A1 (en) | 2019-04-05 | 2020-10-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Diagnostic for childhood risk of autism spectrum disorder |
| EP3948277A4 (en) | 2019-04-05 | 2023-05-24 | Arizona Board of Regents on behalf of Arizona State University | METABOLITES AS DIAGNOSTICS OF AUTISTIC SPECTRUM DISEASE IN CHILDREN WITH GASTROINTESTINAL SYMPTOMS |
| CN113906296B (zh) * | 2019-04-23 | 2024-11-15 | 中国医学科学院北京协和医院 | 基于机器学习的使用代谢物作为标记物的孤独症谱系障碍诊断方法和装置 |
| EP3963323A4 (en) * | 2019-05-02 | 2023-05-31 | Stemina Biomarker Discovery, Inc. | DIAGNOSIS AND TREATMENT OF AUTISTIC SPECTRUM DISEASES RELATED TO ALTERED METABOLIC PATHWAYS |
| EP3980764A4 (en) * | 2019-06-06 | 2023-07-05 | Icahn School of Medicine at Mount Sinai | SYSTEMS AND METHODS FOR DIAGNOSIS OF BIOLOGICAL DISEASES RELATED TO PERIODIC VARIATIONS OF METAL METABOLISM |
| US20220146527A1 (en) * | 2019-09-17 | 2022-05-12 | Chang Gung University | Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms |
| WO2021072351A1 (en) * | 2019-10-11 | 2021-04-15 | Stemina Biomarker Discovery, Inc. | Diagnosis and treatment of autism spectrum disorders using altered ratios of metabolite concentrations |
| US20240369538A1 (en) * | 2019-10-16 | 2024-11-07 | Rene Anand | Live Virus Vaccine Injury Risk |
| CN116547520A (zh) * | 2020-09-21 | 2023-08-04 | 分子优公司 | 孤独症谱系障碍的诊断与治疗方法 |
| CA3193117A1 (en) * | 2020-09-21 | 2022-03-24 | Mohammad Ashraful Anwar | Method of diagnosis and treatment of autism spectrum disorder |
| EP4222501A1 (en) * | 2020-10-24 | 2023-08-09 | Universitätsspital Basel | Method of quantifying lysergic acid diethylamide (lsd) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (o-h-lsd) in human plasma |
| EP4012414A1 (en) * | 2020-12-11 | 2022-06-15 | Stalicla S.A. | Diagnosis of autism spectrum disorder phenotype 1 |
| CN113125588B (zh) * | 2021-03-17 | 2022-01-14 | 广东省农业科学院农业质量标准与监测技术研究所 | 一种代谢组学分析技术判别鸭屎香单丛茶时空分类的应用 |
| KR102530345B1 (ko) * | 2021-08-04 | 2023-05-10 | 단국대학교 천안캠퍼스 산학협력단 | 대사체 프로파일링을 이용한 자폐 스펙트럼 장애의 진단용 조성물 및 이를 포함하는 진단키트 |
| JP2024134052A (ja) * | 2023-03-20 | 2024-10-03 | 株式会社島津製作所 | データ処理方法、データ処理装置およびプログラム |
| US20260017793A1 (en) * | 2024-07-12 | 2026-01-15 | University Of Louisville Research Foundation, Inc. | Computer-aided system and method for determination of autism spectrum disorder severity by assessment module |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686311A (en) * | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
| US6708064B2 (en) * | 2000-02-24 | 2004-03-16 | Ali R. Rezai | Modulation of the brain to affect psychiatric disorders |
| WO2001079837A1 (en) | 2000-04-12 | 2001-10-25 | Repligen Corporation | Methylxanthines in the diagnosis and treatment of autistic disorder |
| WO2001078652A2 (en) | 2000-04-14 | 2001-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US20080154332A1 (en) * | 2001-12-24 | 2008-06-26 | The Cleveland Clinic Foundation | Modulation of the Brain to Affect Psychiatric Disorders and Functions |
| US8131473B1 (en) | 2004-05-20 | 2012-03-06 | Metabolon, Inc. | Data analysis methods for locating entities of interest within large, multivariable datasets |
| GB0504096D0 (en) | 2005-02-28 | 2005-04-06 | Tipogen As | Method |
| WO2006121952A2 (en) | 2005-05-05 | 2006-11-16 | The Regents Of The University Of California | Diagnostic biomarkers for neurodevelopmental disorders |
| US20070023677A1 (en) * | 2005-06-29 | 2007-02-01 | Perkins Patrick D | Multimode ionization source and method for screening molecules |
| US7433787B2 (en) | 2005-08-08 | 2008-10-07 | Metabolon, Inc. | System, method, and computer program product using a database in a computing system to compile and compare metabolomic data obtained from a plurality of samples |
| US7949475B2 (en) | 2005-08-08 | 2011-05-24 | Metabolon Inc. | System and method for analyzing metabolomic data |
| EP1997049B1 (en) | 2006-03-21 | 2019-03-13 | Metabolon Inc. | A system, method, and computer program product for analyzing spectrometry data to indentify and quantify individual components in a sample |
| US20110229883A1 (en) | 2007-04-10 | 2011-09-22 | Bernd Spur | Biochemical Markers for Disease States and Genes for Identification of Biochemical Defects |
| AU2008280806B2 (en) * | 2007-07-26 | 2014-12-11 | Phenomenome Discoveries Inc. | Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders |
| WO2009032722A1 (en) * | 2007-08-29 | 2009-03-12 | The Cleveland Clinic Foundation | Carbamylated proteins and risk of cardiovascular disease |
| US7884318B2 (en) | 2008-01-16 | 2011-02-08 | Metabolon, Inc. | Systems, methods, and computer-readable medium for determining composition of chemical constituents in a complex mixture |
| WO2010045180A1 (en) * | 2008-10-13 | 2010-04-22 | Metabolon, Inc. | Biomarkers for inflammatory bowel disease and methods using the same |
| DK200970026A (en) | 2009-06-12 | 2010-12-13 | Alfa Laval Corp Ab | A centrifugal separator |
| EP2309276A1 (en) * | 2009-09-22 | 2011-04-13 | One Way Liver Genomics, S.L. | Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile |
| US8703424B2 (en) | 2010-03-22 | 2014-04-22 | Stemina Biomarker Discovery, Inc. | Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics |
| WO2011139914A1 (en) | 2010-04-29 | 2011-11-10 | Wisconsin Alumni Research Foundation | Metabolic biomarkers of autism |
| WO2011146683A1 (en) * | 2010-05-19 | 2011-11-24 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
| WO2012015904A2 (en) * | 2010-07-28 | 2012-02-02 | Metabolon, Inc. | Biomarkers for prostate cancer and methods using the same |
| WO2013016700A1 (en) * | 2011-07-27 | 2013-01-31 | The Research Foundation Of State University Of New York | Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc |
| US20140303228A1 (en) * | 2011-10-18 | 2014-10-09 | Metabolon, Inc. | Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same |
| AU2012347557A1 (en) * | 2011-12-09 | 2014-07-03 | Metabolon, Inc. | Biomarkers for kidney cancer and methods using the same |
| CN114949001A (zh) * | 2012-08-29 | 2022-08-30 | 加州理工学院 | 孤独症谱系障碍的诊断和治疗 |
| IN2015DN02868A (enExample) | 2012-09-21 | 2015-09-11 | Univ Toronto | |
| DK2914748T3 (da) * | 2012-11-02 | 2019-06-11 | Stemina Biomarker Discovery Inc | Forudsigelse af udviklingen af toxicitet af farmaceutika for mennesker, under anvendelse af humane stamcellelignende celler og metaboliske forholdstal |
| JP6404834B2 (ja) * | 2013-01-31 | 2018-10-17 | メタボロン，インコーポレイテッド | インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 |
| US9176113B1 (en) * | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US20150294081A1 (en) * | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
-
2014
- 2014-07-03 MX MX2016000293A patent/MX2016000293A/es unknown
- 2014-07-03 US US14/903,717 patent/US10060932B2/en active Active
- 2014-07-03 WO PCT/US2014/045397 patent/WO2015006160A2/en not_active Ceased
- 2014-07-03 CA CA2917483A patent/CA2917483A1/en not_active Abandoned
- 2014-07-03 EP EP14822642.6A patent/EP3019624B1/en not_active Not-in-force
- 2014-07-03 JP JP2016525390A patent/JP6763770B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-27 US US16/047,237 patent/US11268966B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3019624B1 (en) | 2020-09-16 |
| EP3019624A2 (en) | 2016-05-18 |
| US11268966B2 (en) | 2022-03-08 |
| CA2917483A1 (en) | 2015-01-15 |
| US20160169915A1 (en) | 2016-06-16 |
| JP2016530504A (ja) | 2016-09-29 |
| EP3019624A4 (en) | 2017-01-11 |
| US20190072569A1 (en) | 2019-03-07 |
| WO2015006160A2 (en) | 2015-01-15 |
| US10060932B2 (en) | 2018-08-28 |
| WO2015006160A3 (en) | 2015-11-26 |
| JP6763770B2 (ja) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015006160A3 (en) | Biomarkers of autism spectrum disorder | |
| AU2018260845A1 (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| CA2878044C (en) | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| CA2797787A1 (en) | Metabolic biomarkers of autism | |
| GB2519906A (en) | Methods and systems for detecting biological components | |
| BR112017025097A2 (pt) | método para quantificação espectrométrica de massa de analitos extraídos de um dispositivo de microamostragem | |
| MX373957B (es) | Un método in vitro para detectar un biomarcador de cáncer en un sujeto. | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| EP4220170A3 (en) | Method for detecting a solid tumor cancer | |
| EP4450644A3 (en) | Increasing dynamic range for identifying multiple epitopes in cells | |
| BR112015019326A2 (pt) | dispositivo de registro de amostragem e armazenamento para análise de gás respiratório | |
| IN2014MN02101A (enExample) | ||
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| BR112016024730A2 (pt) | dispositivo, método e conjunto de análise imunocromatográfica | |
| MX360479B (es) | Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs. | |
| WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| EP4290231A3 (en) | Method for assessing performance of an instrument with liquid chromatography and mass spectrometry functionalities | |
| BR112018010764A2 (pt) | método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente | |
| HK1204061A1 (en) | Methods and kits for detecting and diagnosing neurotrauma | |
| GB201102693D0 (en) | Method for identifying neonates at risk for necrotizing enterocolitis | |
| CY1121406T1 (el) | Διαγνωση καρδιακης ανεπαρκειας | |
| WO2016118920A3 (en) | Metabolomic based biomarkers for colon cancer detection | |
| EA201691168A1 (ru) | Способы исследования бета-глюкана |